Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
... level. After protective antigen and the anthrax
toxins are produced by the bacteria, protective antigen ... complex that makes it possible for the anthrax
toxins to enter the cells. Raxibacumab blocks the ... antigen to cell surfaces and prevents the anthrax
toxins from entering and killing the cells.
ABOUT ...
Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
... attacks. It specifically targets the deadly
toxins released within the human body by Bacillus ... they are not effective against the deadly
toxins that the bacteria produce. ABthrax targets anthrax
toxins after they are released by the bacteria into the ...
New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
... ABthrax, which specifically targets anthrax
toxins and is being
developed under contract with the ... they
are not effective against the deadly
toxins that the bacteria produce --
the real culprits in ... but are not
effective against the anthrax
toxins once ...
Replidyne's Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
... to stop the production of
destructive intestinal
toxins caused by Clostridium difficile (C.
difficile) ... condition caused by potentially lethal
toxins that enter and
then kill healthy cells in the ... to inhibit growth of the bacteria.
The levels of
toxins were monitored by immunoassays using antibodies ...
ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
... two-way transfer of metabolites. During ELAD therapy the cells metabolize
toxins and synthesize proteins and other liver specific products essential for ... could provide support for patients with severe liver failure by processing
toxins and synthesizing proteins and metabolites that are key products of normal ...
Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
... Canada. The BI/NAP1/027
outbreak strains produce greater amounts of
toxins A and B, have increased
sporulation capacity, and cause more severe ... C. difficile strain (BI/NAP1, 027) that produces
high levels of
toxins poses a real threat to public health and demands
improved infection ...
PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
... However, antibiotic therapy, while useful, is believed to be associated with a number of limitations, including: (1) lack of activity against the
toxins produced by the B. anthracis bacteria, (2) need for long-term dosing to achieve full protection, complicated by side effects and non-compliance (3) ...
Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
... and in the community. It is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria, which produce
toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death. CDI typically develops from the use of broad-spectrum ...
Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
... However, antibiotic therapy, while useful, is believed to be associated with a number of limitations, including: (1) lack of activity against the
toxins produced by the B. anthracis bacteria, (2) need for long-term dosing to achieve full protection, complicated by side effects and non-compliance (3) ...
ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
... bacterium, which under certain circumstances, typically after antibiotic therapy, can colonize the lower gastrointestinal tract where it may produce
toxins which cause inflammation of the colon and diarrhea. Without proper treatment, the associated complications of the disease can be deadly. Advanced ...
Got Pain?
... of Medicine and president of the American Society for Surgery of the Hand (ASSH) is successfully using another type of injection therapy, Botulinum
toxins on patients with nerve pain. The results of this type of less invasive procedure are very favorable. Additionally, Koman said, "nerve pain may be ...
British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection
... the disease.
Currently, scientists know that the bacteria cause disease by sticking to epithelial cells of the gut lining and releasing two
toxins that damage cells leading to the tell-tale symptom of severe diarrhea. However, there is very little known about the ways in which the bacteria ...
PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.
... study data that suggests that initiating and maintaining high urine output during imaging procedures allows the body to rapidly eliminate
toxins in contrast media, reducing their harmful effects. RenalGuard is a fully-automated, real-time matched fluid replacement device intended for ...
PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
... the onset of the illness by attaching to
cells in the infected person, and then is believed to facilitate the entry
of additional destructive
toxins into the cells. Valortim(R) is designed to
target anthrax protective antigen and protect the cells from damage by the
anthrax toxins.
About ...
Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine
... uses an ETEC toxin delivered via a skin patch using the
company's novel transcutaneous immunization (TCI) technology. ETEC causes
illness through the
toxins it produces, including one known as heat-labile
toxin or LT. Iomai's unique patch-based vaccine enables the safe
administration of this potent ...
PLC Systems Announces Approval of First European Study to Evaluate RenalGuard(TM)
... on existing study data that suggests that
initiating and maintaining high urine output during imaging procedures
allows the body to rapidly eliminate
toxins in contrast media, reducing
their harmful effect. RenalGuard is a fully-automated, real-time matched
fluid replacement device intended for ...
Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
... for B-cell modulation in the treatment of
relapsing-remitting MS.
ABthrax(TM) (raxibacumab), a human monoclonal antibody that prevents
anthrax
toxins from entering and killing cells, for the treatment of
anthrax disease
HGS reported in December 2007 that the results of two animal ...
Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device
... of specific molecular weights are expressed through
the micropores, thereby cleansing the blood of harmful impurities (e.g.,
hepatic failure
toxins as well as various mediators of inflammation and
inhibitors of liver regeneration). These substances would otherwise
progressively accumulate in the ...
Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
... swab tests to detect Listeria in
feedlots and E. coli in processing plants. Dr. Nash also developed tests
for strep, whooping cough, salmonella,
toxins and other diagnostics. During
the first Gulf War, he worked on anthrax tests until government funding
dissipated. Along with two others, Dr. Nash ...
PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
... study data that suggests
that initiating and maintaining high urine output during imaging procedures
allows the body to rapidly eliminate
toxins in contrast media, reducing
their harmful effects. RenalGuard is a fully-automated, real-time matched
fluid replacement device intended for ...
Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
... of specific molecular weights are expressed through
the micropores, thereby cleansing the blood of harmful impurities (e.g.,
hepatic failure
toxins as well as various mediators of inflammation and
inhibitors of liver regeneration). These substances would otherwise
progressively accumulate in the ...
Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
... 'energy factories' of body cells. It is believed
that mitochondrial function is decreased in people with Parkinson's disease
and that mitochondrial
toxins induce parkinsonian symptoms in animal
models. Rebecca Pruss, PhD, and her colleagues at Trophos are developing
unique compounds that improve ...
PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
... study data that
suggests that initiating and maintaining high urine output during imaging
procedures allows the body to rapidly eliminate
toxins in contrast media,
reducing their harmful effects. The RenalGuard System(TM) is a
fully-automated, real-time matched fluid replacement device ...
Vital Therapies Announces Presentation of ELAD(R) 'Artificial Liver' Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
... of liver disease. The system consists of four
cartridges containing cells that function like normal human liver
hepatocytes. The cells metabolize
toxins and remove waste products while
delivering essential proteins into the plasma. These cartridges are
incorporated into a blood pumping system at the ...
Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn's Disease
... of Phase 2 trials with
AST-120 in Irritable Bowel Syndrome and Hepatic Encephalopathy. AST-120 is
an oral agent known to adsorb bile acids,
toxins and mediators of
inflammation from the gastrointestinal tract with the potential to address
multiple gastrointestinal diseases. Ocera in-licensed ...
Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
... of specific molecular weights are expressed through
the micropores, thereby cleansing the blood of harmful impurities (e.g.,
hepatic failure
toxins as well as various mediators of inflammation and
inhibitors of liver regeneration). These substances would otherwise
progressively accumulate in the ...
Genzyme Announces Data from First Phase 3 Study of Tolevamer in
Patients with C. difficile Associated Diarrhea
... antibiotic therapy.
Tolevamer is designed to bind and neutralize the
toxins released
by C. difficile that damage the intestine. A ... antibiotics. Once established in the colon, C.
difficile produces
toxins that disrupt the intestinal lining,
causing cell death and inflammation ...
New Analysis of WHI Data Shows Reduced Levels of Coronary Artery
Calcification, a Predictor of Cardiovascular Events, in Women aged
50-59 taking Estrogen Therapy
... also is
developing its calcium phosphate nanotechnology (CaP) for novel
vaccines, including hepatitis B, avian flu and biodefense vaccines
for
toxins such as anthrax, as well as a system for delivering
drugs via alternative routes of administration. Additional
information is available online at ....
DOR BioPharma Announces Publication Describing Results of Its
Multivalent Botulinum Toxin Vaccine BT-VACC
... of a large population. The only vaccine
available is an experimental vaccine based on inactivation of a
mixture of serotypes of the natural
toxins that is given by
injection, is not licensed by the FDA and cannot be used for
widespread immunization. New multivalent vaccines based on
non-toxic ...
DOR BioPharma Announces Issuance of European Patent for Its Oral
Multivalent Botulinum Toxin Vaccine BT-VACC
... of a large population. The only vaccine
available is an experimental vaccine based on inactivation of a
mixture of serotypes of the natural
toxins that is given by
injection, is not licensed by the FDA and cannot be used for
widespread immunization. New multivalent vaccines based on
non-toxic ...
BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
... also is
developing its calcium phosphate nanotechnology (CaP) for novel
vaccines, including hepatitis B, avian flu and biodefense vaccines
for
toxins such as anthrax, as well as a system for delivering
drugs via alternative routes of administration. Additional
information is available online at ....